MXCT Stock Overview
A life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
MaxCyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.65 |
| 52 Week High | UK£4.08 |
| 52 Week Low | UK£1.60 |
| Beta | 1.13 |
| 1 Month Change | -14.51% |
| 3 Month Change | -49.70% |
| 1 Year Change | -56.00% |
| 3 Year Change | -55.41% |
| 5 Year Change | -1.49% |
| Change since IPO | 115.69% |
Recent News & Updates
Recent updates
SeQure Dx Acquisition And CASGEVY Will Boost Cell Therapy Prospects
Mar 27 Acquisition of SeQure Dx and SPL portfolio expansion could drive future revenue growth through improved offerings and new clinical progressions.MaxCyte, Inc.'s (LON:MXCT) Stock Retreats 26% But Revenues Haven't Escaped The Attention Of Investors
Feb 28
Should You Investigate MaxCyte, Inc. (LON:MXCT) At UK£3.65?
Jan 29We're Not Very Worried About MaxCyte's (LON:MXCT) Cash Burn Rate
Jan 07Getting In Cheap On MaxCyte, Inc. (LON:MXCT) Might Be Difficult
Dec 10MaxCyte, Inc. (LON:MXCT) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 09Investors Appear Satisfied With MaxCyte, Inc.'s (LON:MXCT) Prospects As Shares Rocket 27%
May 30Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results
May 10Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term
Mar 14Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation
Mar 07Analysts Have Just Cut Their MaxCyte, Inc. (LON:MXCT) Revenue Estimates By 22%
Oct 07Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation
Aug 12MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%
May 15Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%
May 14We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
Apr 27Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth
Nov 20Shareholder Returns
| MXCT | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -8.3% | -1.4% | 1.6% |
| 1Y | -56.0% | -12.8% | 0.7% |
Return vs Industry: MXCT underperformed the UK Life Sciences industry which returned -12.8% over the past year.
Return vs Market: MXCT underperformed the UK Market which returned 0.7% over the past year.
Price Volatility
| MXCT volatility | |
|---|---|
| MXCT Average Weekly Movement | 7.9% |
| Life Sciences Industry Average Movement | 7.5% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: MXCT has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: MXCT's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 114 | Maher Masoud | www.maxcyte.com |
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
MaxCyte, Inc. Fundamentals Summary
| MXCT fundamental statistics | |
|---|---|
| Market cap | UK£175.43m |
| Earnings (TTM) | -UK£31.48m |
| Revenue (TTM) | UK£28.38m |
6.2x
P/S Ratio-5.6x
P/E RatioIs MXCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MXCT income statement (TTM) | |
|---|---|
| Revenue | US$37.68m |
| Cost of Revenue | US$7.19m |
| Gross Profit | US$30.48m |
| Other Expenses | US$72.27m |
| Earnings | -US$41.79m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 80.91% |
| Net Profit Margin | -110.92% |
| Debt/Equity Ratio | 0% |
How did MXCT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 19:02 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MaxCyte, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Paul Cuddon | Numis Securities Ltd. |